Abstract
Background: There is scarcity of data on outcome of COVID-19 in patients with hematological malignancies. Primary objective of study was to analyse the 14-day and 28-day mortality. Secondary objectives were to correlate age, comorbidities and remission status with outcome.
Methods: Retrospective multicentre observational study conducted in 11 centres across India. Total 130 patients with hematological malignancies and COVID-19 were enrolled.
Results: Fever and cough were commonest presentation. Eleven percent patients were incidentally detected. Median age of our cohort was 49.5 years. Most of our patients had a lymphoid malignancy (n = 91). One-half patients (52%) had mild infection, while moderate and severe infections contributed to one-fourth each. Sixty seven patients (52%) needed oxygen For treatment of COVID-19 infection, half(n = 66) received antivirals. Median time to RT-PCR COVID-19 negativity was 17 days (7-49 days). Nearly three-fourth (n = 95) of our patients were on anticancer treatment at time of infection, of which nearly two-third (n = 59;64%) had a delay in chemotherapy. Overall, 20% (n = 26) patients succumbed. 14-day survival and 28-day survival for whole cohort was 85.4% and 80%, respectively. One patient succumbed outside the study period on day 39. Importantly, death rate at 1 month was 50% and 60% in relapse/refractory and severe disease cohorts, respectively. Elderly patients(age ≥ 60) (p = 0.009), and severe COVID-19 infection (p = 0.000) had a poor 14-day survival. The 28-day survival was significantly better for patients in remission (p = 0.04), non-severe infection (p = 0.00), and age < 60 years (p = 0.05).
Conclusions: Elderly patients with hematological malignancy and severe covid-19 have worst outcomes specially when disease is not in remission.
Keywords: COVID-19; Comorbidity; Hematology; Remission; Survival.
【저자키워드】 COVID-19, Comorbidity, hematology, Survival., Remission, 【초록키워드】 Treatment, Severe infection, Hematological malignancy, Hematological malignancies, antivirals, elderly, India, Infection, 28-day mortality, oxygen, outcome, cough, RT-PCR, Chemotherapy, Cohort, survival, COVID-19 infection, Patient, age, multicentre, disease, moderate, mild infection, severe disease, malignancy, death rate, Severe COVID-19 Infection, one patient, study period, cohorts, anticancer, negativity, lymphoid, MOST, Seven, enrolled, significantly, conducted, contributed, Total, COVID-19 in patient, Secondary objective, 【제목키워드】 Hematological malignancy, outcome, age, Effect, COVID-19 in patient,